GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RP-3 overview
RP-3 is under development for the treatment of advanced solid tumors including head and neck cancer, lung cancer, breast cancer, gastric cancer, recurrent head and neck cancer squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic hepatocellular carcinoma, micro-satellite stable colorectal cancer (CRC), melanoma and liver metastases, soft tissue sarcomas including leiomyosarcoma, osteosarcoma, chondrosarcoma, myxofibrosarcoma and epithelioid sarcomas. RP3 is a genetically modified herpes simplex type 1 virus (HSV-1) that expresses exogenous genes (anti-CTLA-4 antibody, 4-1BB ligand and CD40 ligand). It is administered by intratumor route. The drug candidate is an oncolytic immunotherapy and is developed based on Immulytic platform.
Replimune overview
Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co-stimulatory ligands. Its Immulytic platform is designed to maximize systemic immune activation in tumor neoantigens, through viral-mediated immunogenic tumor cell killing and deliver optimal combinations of immune-activating proteins into a tumor and draining lymph nodes. Replimune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of RP-3’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.